Legend Biotech (LEGN) P/B ratio

P/B ratio today
3.0×

Legend Biotech (LEGN) trades at 3.0× its book value per share at the end of fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/B ratio was 4.0×. That is 30.1% lower than the 5.7× of fiscal 2024. Figures as of 18 Nov 2026, 09:31 UTC, from Yahoo Finance.

Key facts

P/B ratio today
3.0×
P/B ratio, fiscal 2025
4.0×
Change on fiscal 2024
−30.1%
Highest on record
10.7×fiscal 2022
Lowest on record
4.0×fiscal 2025
Fiscal years on record
42022–2025

Figures as of . Statements from Yahoo Finance. Figures, not advice.

Legend Biotech P/B ratio, in more detail

Today's figure is 25.9% below the fiscal 2025 year-end.

Across the 4 fiscal year-ends on record (2022–2025), the highest was 10.7× in fiscal 2022 and the lowest 4.0× in fiscal 2025. Today's P/B ratio is at or below every one of the 4 fiscal year-ends on record; their median is 7.1×.

History · 4 fiscal years

P/B ratio at each fiscal year-end

The last point is today's figure; the others are fiscal year-ends.

Legend Biotech P/B ratio, year by year

Legend Biotech (LEGN) P/B ratio by fiscal year
Fiscal yearP/B ratioChangeYear endedShare price at year-endBook value per share
Today3.0×—$16.11—
20254.0× 30.1% down$21.74$5.44
20245.7× 32.5% down$32.54$5.69
20238.5× 20.6% down$60.17$7.11
202210.7×—$49.92$4.68

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

The P/B ratio is the share price divided by book value per share — shareholders' equity on the balance sheet divided by the share count — at each fiscal year-end; a year with negative equity has no P/B.

How to read it

It compares the price with the accounting value of what the company owns net of what it owes, and matters most for banks, insurers and other balance-sheet businesses.

P/B ratio at health care companies of similar size

P/B ratio of Legend Biotech and comparable companies
CompanyP/B ratio
Heartflow HTFL13.8×
CRISPR Therapeutics CRSP2.0×
Travere Therapeutics TVTX42.7×
Option Care Health OPCH3.6×
Legend Biotech LEGN3.1×
Definium Therapeutics DFTX12.1×

Today's market value divided by shareholders' equity at the latest fiscal year-end. A company whose statements are in another currency than its shares is left out.

More on LEGN

Legend Biotech, figure by figure

Legend Biotech (LEGN) overview: price, valuation and scorecardAll health care companies by market value

Legend Biotech P/B ratio: questions and answers

What is Legend Biotech's P/B ratio?

Legend Biotech (LEGN) trades at 3.0× its book value per share at the end of fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/B ratio was 4.0×. That is 30.1% lower than the 5.7× of fiscal 2024.

Is Legend Biotech's P/B ratio high or low compared with its own history?

Today's P/B ratio is at or below every one of the 4 fiscal year-ends on record; their median is 7.1×.

What are the highest and lowest P/B ratio figures on record for Legend Biotech?

Across the 4 fiscal year-ends on record (2022–2025), the highest was 10.7× in fiscal 2022 and the lowest 4.0× in fiscal 2025.

How is Legend Biotech's P/B ratio calculated?

The P/B ratio is the share price divided by book value per share — shareholders' equity on the balance sheet divided by the share count — at each fiscal year-end; a year with negative equity has no P/B. For Legend Biotech it is on record here for 4 fiscal years, 2022 to 2025.

Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Legend Biotech (LEGN) P/B ratio”, data as of 18 November 2026. https://funkfolio.com/stock/LEGN/pb-ratio

Underlying data: Yahoo Finance.